Click for best price
lmmune Checkpoint Inhibitors Market Size, Share 2024
The global lmmune Checkpoint Inhibitors market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
PD-1 Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of lmmune Checkpoint Inhibitors include AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer and Sanofi, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for lmmune Checkpoint Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding lmmune Checkpoint Inhibitors. This report contains market size and forecasts of lmmune Checkpoint Inhibitors in global, including the following market information:
Global lmmune Checkpoint Inhibitors Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the lmmune Checkpoint Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global lmmune Checkpoint Inhibitors Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global lmmune Checkpoint Inhibitors Market Segment Percentages, by Type, 2023 (%)
PD-1
PD-L1
CTLA-4
Global lmmune Checkpoint Inhibitors Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global lmmune Checkpoint Inhibitors Market Segment Percentages, by Application, 2023 (%)
Lung Cancer
Melanoma
Others
Global lmmune Checkpoint Inhibitors Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global lmmune Checkpoint Inhibitors Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies lmmune Checkpoint Inhibitors revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies lmmune Checkpoint Inhibitors revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bristol-Myers Squibb
Roche Holdings AG
Novartis AG
Pfizer
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of lmmune Checkpoint Inhibitors, market overview.
Chapter 2: Global lmmune Checkpoint Inhibitors market size in revenue.
Chapter 3: Detailed analysis of lmmune Checkpoint Inhibitors company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of lmmune Checkpoint Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
lmmune Checkpoint Inhibitors Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
61 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 lmmune Checkpoint Inhibitors Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global lmmune Checkpoint Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global lmmune Checkpoint Inhibitors Overall Market Size
2.1 Global lmmune Checkpoint Inhibitors Market Size: 2023 VS 2030
2.2 Global lmmune Checkpoint Inhibitors Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top lmmune Checkpoint Inhibitors Players in Global Market
3.2 Top Global lmmune Checkpoint Inhibitors Companies Ranked by Revenue
3.3 Global lmmune Checkpoint Inhibitors Revenue by Companies
3.4 Top 3 and Top 5 lmmune Checkpoint Inhibitors Companies in Global Market, by Revenue in 2023
3.5 Global Companies lmmune Checkpoint Inhibitors Product Type
3.6 Tier 1, Tier 2 and Tier 3 lmmune Checkpoint Inhibitors Players in Global Market
3.6.1 List of Global Tier 1 lmmune Checkpoint Inhibitors Companies
3.6.2 List of Global Tier 2 and Tier 3 lmmune Checkpoint Inhibitors Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global lmmune Checkpoint Inhibitors Market Size Markets, 2023 & 2030
4.1.2 PD-1
4.1.3 PD-L1
4.1.4 CTLA-4
4.2 By Type - Global lmmune Checkpoint Inhibitors Revenue & Forecasts
4.2.1 By Type - Global lmmune Checkpoint Inhibitors Revenue, 2019-2024
4.2.2 By Type - Global lmmune Checkpoint Inhibitors Revenue, 2025-2030
4.2.3 By Type - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global lmmune Checkpoint Inhibitors Market Size, 2023 & 2030
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Others
5.2 By Application - Global lmmune Checkpoint Inhibitors Revenue & Forecasts
5.2.1 By Application - Global lmmune Checkpoint Inhibitors Revenue, 2019-2024
5.2.2 By Application - Global lmmune Checkpoint Inhibitors Revenue, 2025-2030
5.2.3 By Application - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global lmmune Checkpoint Inhibitors Market Size, 2023 & 2030
6.2 By Region - Global lmmune Checkpoint Inhibitors Revenue & Forecasts
6.2.1 By Region - Global lmmune Checkpoint Inhibitors Revenue, 2019-2024
6.2.2 By Region - Global lmmune Checkpoint Inhibitors Revenue, 2025-2030
6.2.3 By Region - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America lmmune Checkpoint Inhibitors Revenue, 2019-2030
6.3.2 US lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.3.3 Canada lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.3.4 Mexico lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe lmmune Checkpoint Inhibitors Revenue, 2019-2030
6.4.2 Germany lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4.3 France lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4.4 U.K. lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4.5 Italy lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4.6 Russia lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4.7 Nordic Countries lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.4.8 Benelux lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia lmmune Checkpoint Inhibitors Revenue, 2019-2030
6.5.2 China lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.5.3 Japan lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.5.4 South Korea lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.5.5 Southeast Asia lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.5.6 India lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America lmmune Checkpoint Inhibitors Revenue, 2019-2030
6.6.2 Brazil lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.6.3 Argentina lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa lmmune Checkpoint Inhibitors Revenue, 2019-2030
6.7.2 Turkey lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.7.3 Israel lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.7.4 Saudi Arabia lmmune Checkpoint Inhibitors Market Size, 2019-2030
6.7.5 UAE lmmune Checkpoint Inhibitors Market Size, 2019-2030
7 lmmune Checkpoint Inhibitors Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca lmmune Checkpoint Inhibitors Major Product Offerings
7.1.4 AstraZeneca lmmune Checkpoint Inhibitors Revenue in Global Market (2019-2024)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Company Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb lmmune Checkpoint Inhibitors Major Product Offerings
7.2.4 Bristol-Myers Squibb lmmune Checkpoint Inhibitors Revenue in Global Market (2019-2024)
7.2.5 Bristol-Myers Squibb Key News & Latest Developments
7.3 Roche Holdings AG
7.3.1 Roche Holdings AG Company Summary
7.3.2 Roche Holdings AG Business Overview
7.3.3 Roche Holdings AG lmmune Checkpoint Inhibitors Major Product Offerings
7.3.4 Roche Holdings AG lmmune Checkpoint Inhibitors Revenue in Global Market (2019-2024)
7.3.5 Roche Holdings AG Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG lmmune Checkpoint Inhibitors Major Product Offerings
7.4.4 Novartis AG lmmune Checkpoint Inhibitors Revenue in Global Market (2019-2024)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer lmmune Checkpoint Inhibitors Major Product Offerings
7.5.4 Pfizer lmmune Checkpoint Inhibitors Revenue in Global Market (2019-2024)
7.5.5 Pfizer Key News & Latest Developments
7.6 Sanofi
7.6.1 Sanofi Company Summary
7.6.2 Sanofi Business Overview
7.6.3 Sanofi lmmune Checkpoint Inhibitors Major Product Offerings
7.6.4 Sanofi lmmune Checkpoint Inhibitors Revenue in Global Market (2019-2024)
7.6.5 Sanofi Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. lmmune Checkpoint Inhibitors Market Opportunities & Trends in Global Market
Table 2. lmmune Checkpoint Inhibitors Market Drivers in Global Market
Table 3. lmmune Checkpoint Inhibitors Market Restraints in Global Market
Table 4. Key Players of lmmune Checkpoint Inhibitors in Global Market
Table 5. Top lmmune Checkpoint Inhibitors Players in Global Market, Ranking by Revenue (2023)
Table 6. Global lmmune Checkpoint Inhibitors Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global lmmune Checkpoint Inhibitors Revenue Share by Companies, 2019-2024
Table 8. Global Companies lmmune Checkpoint Inhibitors Product Type
Table 9. List of Global Tier 1 lmmune Checkpoint Inhibitors Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 lmmune Checkpoint Inhibitors Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - lmmune Checkpoint Inhibitors Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - lmmune Checkpoint Inhibitors Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - lmmune Checkpoint Inhibitors Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - lmmune Checkpoint Inhibitors Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global lmmune Checkpoint Inhibitors Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global lmmune Checkpoint Inhibitors Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2025-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca lmmune Checkpoint Inhibitors Product Offerings
Table 32. AstraZeneca lmmune Checkpoint Inhibitors Revenue (US$, Mn) & (2019-2024)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Bristol-Myers Squibb Company Summary
Table 35. Bristol-Myers Squibb lmmune Checkpoint Inhibitors Product Offerings
Table 36. Bristol-Myers Squibb lmmune Checkpoint Inhibitors Revenue (US$, Mn) & (2019-2024)
Table 37. Bristol-Myers Squibb Key News & Latest Developments
Table 38. Roche Holdings AG Company Summary
Table 39. Roche Holdings AG lmmune Checkpoint Inhibitors Product Offerings
Table 40. Roche Holdings AG lmmune Checkpoint Inhibitors Revenue (US$, Mn) & (2019-2024)
Table 41. Roche Holdings AG Key News & Latest Developments
Table 42. Novartis AG Company Summary
Table 43. Novartis AG lmmune Checkpoint Inhibitors Product Offerings
Table 44. Novartis AG lmmune Checkpoint Inhibitors Revenue (US$, Mn) & (2019-2024)
Table 45. Novartis AG Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer lmmune Checkpoint Inhibitors Product Offerings
Table 48. Pfizer lmmune Checkpoint Inhibitors Revenue (US$, Mn) & (2019-2024)
Table 49. Pfizer Key News & Latest Developments
Table 50. Sanofi Company Summary
Table 51. Sanofi lmmune Checkpoint Inhibitors Product Offerings
Table 52. Sanofi lmmune Checkpoint Inhibitors Revenue (US$, Mn) & (2019-2024)
Table 53. Sanofi Key News & Latest Developments
List of Figures
Figure 1. lmmune Checkpoint Inhibitors Segment by Type in 2023
Figure 2. lmmune Checkpoint Inhibitors Segment by Application in 2023
Figure 3. Global lmmune Checkpoint Inhibitors Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global lmmune Checkpoint Inhibitors Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global lmmune Checkpoint Inhibitors Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by lmmune Checkpoint Inhibitors Revenue in 2023
Figure 8. By Type - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 9. By Application - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 10. By Type - Global lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 12. By Application - Global lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 14. By Region - Global lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 15. By Country - North America lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 16. US lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 17. Canada lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 20. Germany lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 21. France lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 23. Italy lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 24. Russia lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 28. China lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 29. Japan lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 32. India lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 34. Brazil lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa lmmune Checkpoint Inhibitors Revenue Market Share, 2019-2030
Figure 37. Turkey lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 38. Israel lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 40. UAE lmmune Checkpoint Inhibitors Revenue, (US$, Mn), 2019-2030
Figure 41. AstraZeneca lmmune Checkpoint Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Bristol-Myers Squibb lmmune Checkpoint Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Roche Holdings AG lmmune Checkpoint Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novartis AG lmmune Checkpoint Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Pfizer lmmune Checkpoint Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Sanofi lmmune Checkpoint Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
